{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+A+Bladder+Cancer&page=2", "query": { "condition": "Stage IV A Bladder Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+A+Bladder+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T03:00:38.522Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00016237", "title": "Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Kidney Cancer", "Lung Cancer" ], "interventions": [ { "name": "tucotuzumab celmoleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • New York, New York", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016237" }, { "nct_id": "NCT03513952", "title": "Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Bladder Urothelial Carcinoma", "Advanced Ureter Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Unresectable Bladder Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Glycosylated Recombinant Human Interleukin-7", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography and Computed Tomography Scan", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2019-06-05", "completion_date": "2024-04-01", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 9, "location_summary": "Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03513952" }, { "nct_id": "NCT06414317", "title": "An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Locally Advanced Bladder Carcinoma", "Metastatic Bladder Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Unresectable Bladder Carcinoma" ], "interventions": [ { "name": "Assessment of Distress", "type": "PROCEDURE" }, { "name": "Consultation Visit", "type": "OTHER" }, { "name": "Nutritional Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Supportive Care", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2024-01-12", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414317" }, { "nct_id": "NCT02717156", "title": "Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Bladder Urothelial Carcinoma", "Prostate Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2016-11-21", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02717156" }, { "nct_id": "NCT00003167", "title": "Gene Therapy in Treating Patients With Advanced Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Bladder Cancer", "Stage I Bladder Cancer", "Stage II Bladder Cancer", "Stage III Bladder Cancer", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder" ], "interventions": [ { "name": "Ad5CMV-p53 gene", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "1998-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003167" }, { "nct_id": "NCT04940299", "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Bladder Carcinoma", "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Renal Pelvis Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Malignant Solid Neoplasm", "Metastatic Bladder Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Melanoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v6", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-09-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04940299" }, { "nct_id": "NCT06630416", "title": "Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Bladder Urothelial Carcinoma", "Metastatic Malignant Solid Neoplasm", "Stage IV Bladder Cancer AJCC v8", "MTAP Deletion" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2024-11-27", "completion_date": "2030-05-10", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 2, "location_summary": "Chicago, Illinois • Orland Park, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Orland Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630416" }, { "nct_id": "NCT06349642", "title": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Early Stage Triple-Negative Breast Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Skin Neoplasm", "Metastatic Malignant Solid Neoplasm", "Resectable Lung Non-Small Cell Carcinoma", "Early Stage Lung Non-Small Cell Carcinoma", "Resectable Malignant Solid Neoplasm", "Resectable Triple-Negative Breast Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Recurrent Cervical Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Malignant Skin Neoplasm", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Tissue Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2024-04-24", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06349642" }, { "nct_id": "NCT00004203", "title": "Oxaliplatin in Treating Patients With Metastatic Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Transitional Cell Cancer of the Renal Pelvis and Ureter" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2000-02", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 11, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004203" }, { "nct_id": "NCT00003103", "title": "Chemotherapy in Treating Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Colorectal Cancer", "Esophageal Cancer", "Head and Neck Cancer", "Kidney Cancer", "Lung Cancer", "Ovarian Cancer", "Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "oblimersen sodium", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "1997-08", "completion_date": "2002-08", "has_results": false, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-09-28T03:00:38.522Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003103" } ] }